Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Bolt Biotherapeutics, Inc. Common Stock

BOLT

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Last trade $5.71
Day change -$0.09 (-1.55%)
Day range $5.60 – $5.93
Volume 50,972
Market cap $15M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$15.12M
Price / earnings
—
Price / book
1.2×
Price / sales
3.22×
EV / sales
0.48×
EV / EBITDA
-0.08×

Profitability

Earnings per share
-$11.02
Return on assets
-71.23%
Return on equity
-227.37%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.61×
Quick ratio
2.61×
Cash ratio
1.63×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.54M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BOLT, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$5K$26K$2.5M$2.17M$1.8M$1.22M$0$1.14M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$5K$26K$2.5M$2.17M$1.8M$1.22M$0$1.14M
Selling, general and administrative$2.42M$2.8M$3.12M$3.34M$3.52M$3.83M$3.95M$3.8M
Research and development$5.15M$4.83M$4.99M$6.54M$7.5M$9.51M$11.72M$13.79M
Total operating expenses$8.38M$7.63M$9.59M$9.87M$11.01M$13.34M$16.92M$17.58M
Operating income-$8.37M-$7.6M-$7.09M-$7.7M-$9.21M-$12.12M-$16.92M-$16.44M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$7.72M-$7.24M-$6.63M-$7.14M-$8.56M-$11.04M-$15.94M-$15.18M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.72M-$7.24M-$6.63M-$7.14M-$8.56M-$11.04M-$15.94M-$15.18M
Net income attributable to common shareholders-$7.72M-$7.24M-$6.63M-$7.14M-$8.56M-$11.04M-$15.94M-$15.18M
EBITDA-$7.4M-$7.4M-$5.35M-$7.41M-$8.86M-$11.72M-$15.24M-$16M
Basic earnings per share-$4.57-$4.31-$3.84-$3.72-$4.46-$5.76-$8.32-$7.93
Diluted earnings per share-$4.57-$4.31-$3.84-$3.72-$4.46-$5.76-$8.32-$7.93

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.22, with revenues of $14.27 million falling 10.25% short of expectations. The stock has declined 45.8% year-to-date, significantly underperforming the S&P 500's 7.8% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.

Zacks Investment Research

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates

Caribou Biosciences reported a Q3 loss of $0.25 per share, beating consensus estimates of $0.27 loss, with a 7.41% earnings surprise. Revenue came in at $1.61 million, surpassing estimates by 7.13%, though down from $2.2 million year-ago. The stock has declined 72.1% year-to-date and carries a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies reported Q3 2026 earnings of $0.02 per share, beating consensus estimates of a $0.10 loss, with a 120% earnings surprise. Revenues of $83.9 million exceeded estimates by 16.81%, though down from $93.97 million year-over-year. The stock has gained 58.9% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 9, 20251-for-20reverse split